Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs ESTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESTA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–1 Matrix Metrics)

ESTA Overall Winner 6-Pillar Tally: RBOT.WS 0 – 6 ESTA Matrix Metrics: RBOT.WS 1 – 7 ESTA

As of Nov 20, 2026, Establishment Labs Holdings Inc. (ESTA) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ESTA carries 35.7/100 (SELL) at $69.14 (N/M Forward P/E, -6.6% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ESTA 35.7/100 SELL), ESTA captures the overall institutional head-to-head verdict (7–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-6.6% vs. N/A operating margin) and revenue trajectory (+33.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs ESTA
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ESTA NASDAQ Head-to-Head Winner
Establishment Labs Holdings Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$69.14
-0.68% 1D
Market Cap $2.1B
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 1.49β · 57% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 35.0 Fund 40.0 Flow 61.0 Mom 21.4
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.4 · SMA20: $67.41 · SMA50: $65.69

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 6 ESTA)

Columns: Metric · RBOT.WS · ESTA
1. Valuation Multiples ESTA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 8.6x
2. Growth & Scale ESTA
Revenue Growth (YoY) N/A +33.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $264M
Market Cap N/A $2.1B
3. Profitability & Quality ESTA
Gross Margin N/A 70.2%
Operating Margin N/A -6.6%
Net Profit Margin N/A -14.6%
Return on Equity (ROE) N/A -240.7%
4. Balance Sheet & Cash Flow ESTA
Cash Generation (TTM) N/A -$23M
Cash Flow Margin N/A -8.8%
Net Cash / Leverage N/A ROE $194M Net Debt (17.28x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESTA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 58.9% (5th %ile)
Put/Call OI Skew N/A 0.05x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ESTA
OpEx & R&D Intensity N/A 76.8% of Rev ($203M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs ESTA (7)
Institutional Metric RBOT.WS ESTA Criterion Row Edge
Market Capitalization
Scale
N/A $2.1B Larger Scale ESTA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +33.9% Higher Growth ESTA
Operating Margin (TTM)
Profitability
N/A -6.6% Higher Margin ESTA
Net Profit Margin
Profitability
N/A -14.6% Higher Margin ESTA
Return on Equity (ROE)
Capital Efficiency
N/A -240.7% Higher ROE ESTA
52-Week Range Position
Momentum
0% ($0–$0) 36% ($53–$98) Stronger Trend ESTA
Beta / 30D Volatility
Risk Regime
N/A 1.49β · 57% Vol Lower Realized Risk ESTA
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 35.7 / 100 (SELL) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $264M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 70.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$23M ($194M Net Debt (17.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ESTA +76.84 pp
RBOT.WS: -67.2% · ESTA: +9.64%
3M Horizon ESTA +76.84 pp
RBOT.WS: -67.2% · ESTA: +9.64%
6M Horizon ESTA +76.84 pp
RBOT.WS: -67.2% · ESTA: +9.64%
1Y Horizon ESTA +76.84 pp
RBOT.WS: -67.2% · ESTA: +9.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs ESTA. Trailing 12-month operating profitability (RBOT.WS N/A vs ESTA -6.6%) and valuation multiples (RBOT.WS N/M vs ESTA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ESTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin70.2%
Op. Margin-6.6%
ROE / Fwd P/E-240.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESTA CONSOLIDATION
105d in phase · OBV DISTRIBUTION
Current IV 58.9%
IV Percentile 5th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ESTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ESTA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.1B market capitalization and -6.6% operating margin.
OpEx & R&D Reinvestment 76.8% of Rev ($203M)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs ESTA Key Questions & Quantitative Answers

As of Nov 20, 2026, Establishment Labs Holdings Inc. (ESTA) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ESTA carries 35.7/100 (SELL) at $69.14 (N/M Forward P/E, -6.6% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ESTA 35.7/100 SELL), ESTA captures the overall institutional head-to-head verdict (7–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-6.6% vs. N/A operating margin) and revenue trajectory (+33.9% vs. N/A YoY).

ESTA leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ESTA at +33.9% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (70.2% gross margin, -6.6% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $264M for ESTA. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 76.8% of Rev ($203M) (0 disclosures) for ESTA.

ESTA screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ESTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.6x EV/Revenue (-8.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus ESTA (-240.7% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ESTA carries 58.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.49β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.